Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SETH A WANDER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1790123792
CMS profile
841116
Location
BOSTON, MA

General Payments · PY2018–2024

$404,646.64

  • Reported across 150 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$32,375.47

25 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Genentech USA, Inc. $6,288.72 2
Stemline Therapeutics Inc. $5,808.98 6
Eli Lilly and Company $5,241.55 3
Lilly USA, LLC $5,200.00 2
NOVARTIS PHARMACEUTICALS CORPORATION $3,712.50 1
Genentech, Inc. $2,541.85 2
Gilead Sciences, Inc. $1,890.00 2
Acerta Pharma LLC $1,643.04 5
PUMA BIOTECHNOLOGY, INC. $29.33 1
PFIZER INC. $19.50 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $49,741.98 19
PY2019 $29,231.08 11
PY2020 $64,744.50 13
PY2021 $81,019.00 31
PY2022 $88,327.18 26
PY2023 $59,207.43 25
PY2024 $32,375.47 25

Payment records · PY2024 (25)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $94.05 01/30/2024 Food and Beverage Undisputed 01/23/2026 1105379913 CMS
AstraZeneca Pharmaceuticals LP $111.05 05/14/2024 Food and Beverage Undisputed 01/23/2026 1104409787 CMS
AstraZeneca Pharmaceuticals LP $23.26 05/14/2024 Food and Beverage Undisputed 01/23/2026 1104482614 CMS
AstraZeneca Pharmaceuticals LP $1,370.00 07/05/2024 Consulting Fee Undisputed 01/23/2026 1105899670 CMS
AstraZeneca Pharmaceuticals LP $44.68 12/10/2024 Food and Beverage Undisputed 01/23/2026 1104641235 CMS
Eli Lilly and Company $3,200.00 04/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135420833 CMS
Eli Lilly and Company $2,000.00 08/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135420835 CMS
Eli Lilly and Company $41.55 12/10/2024 Food and Beverage Undisputed 01/23/2026 1135346070 CMS
Genentech USA, Inc. $6,080.00 03/14/2024 Consulting Fee Undisputed 01/23/2026 1133110186 CMS
Genentech USA, Inc. $208.72 03/14/2024 Food and Beverage Undisputed 01/23/2026 1133110190 CMS
Genentech, Inc. $2,470.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1133110194 CMS
Genentech, Inc. $71.85 12/09/2024 Food and Beverage Undisputed 01/23/2026 1133110198 CMS
Gilead Sciences, Inc. $150.00 12/12/2024 Food and Beverage Undisputed 01/23/2026 1133793687 CMS
Gilead Sciences, Inc. $1,740.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 1133599259 CMS
Lilly USA, LLC $1,600.00 02/16/2024 Consulting Fee Undisputed 01/23/2026 1135413115 CMS
Lilly USA, LLC $3,600.00 06/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135385035 CMS
Novartis Pharmaceuticals Corporation $3,712.50 06/13/2024 Consulting Fee Undisputed 01/23/2026 1087427592 CMS
PFIZER INC. $19.50 05/31/2024 Food and Beverage Undisputed 01/23/2026 1131598061 CMS
PUMA BIOTECHNOLOGY, INC. $29.33 12/12/2024 Food and Beverage Undisputed 01/23/2026 1113837864 CMS
Stemline Therapeutics Inc. $130.16 05/02/2024 Food and Beverage Undisputed 01/23/2026 1142964213 CMS
Stemline Therapeutics Inc. $1,950.00 06/24/2024 Consulting Fee Undisputed 01/23/2026 1142964220 CMS
Stemline Therapeutics Inc. $47.51 08/22/2024 Food and Beverage Undisputed 01/23/2026 1142964228 CMS
Stemline Therapeutics Inc. $97.01 08/24/2024 Food and Beverage Undisputed 01/23/2026 1142964224 CMS
Stemline Therapeutics Inc. $74.30 09/05/2024 Food and Beverage Undisputed 01/23/2026 1142964231 CMS
Stemline Therapeutics Inc. $3,510.00 09/13/2024 Consulting Fee Undisputed 01/23/2026 1142964217 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.